{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:16Z","timestamp":1791942856089,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12325-024-02946-2","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T11:02:01Z","timestamp":1722423721000},"page":"3645-3663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7234-8910","authenticated-orcid":false,"given":"Tobias J.","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano-Subias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina C.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Remenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"38","key":"2946_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"1","key":"2946_CR2","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.","journal-title":"Eur Respir J"},{"key":"2946_CR3","unstructured":"Uptravi SmPC. Uptravi\u00ae (selexipag) Summary of product characteristics (June 2022) 2022."},{"key":"2946_CR4","unstructured":"Uptravi\u00ae (selexipag) Full Prescribing Information. 2022. Uptravi\u00ae (selexipag) full prescribing information. Actelion Pharmaceuticals US, Inc."},{"issue":"2","key":"2946_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.healun.2023.09.016","volume":"43","author":"V McLaughlin","year":"2024","unstructured":"McLaughlin V, Farber HW, Highland KB, et al. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant. 2024;43(2):272\u201383.","journal-title":"J Heart Lung Transplant"},{"key":"2946_CR6","doi-asserted-by":"publisher","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","volume":"53","author":"N Gali\u00e8","year":"2019","unstructured":"Gali\u00e8 N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889.","journal-title":"Eur Respir J"},{"issue":"26","key":"2946_CR7","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"2946_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1183\/23120541.00456-2022","volume":"9","author":"JG Coghlan","year":"2023","unstructured":"Coghlan JG, Gaine S, Channick R, et al. Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension. ERJ Open Res. 2023;9(1):456\u20132022.","journal-title":"ERJ Open Res"},{"issue":"4","key":"2946_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","volume":"39","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant. 2020;39(4):300\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"2946_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12325-023-02730-8","volume":"41","author":"A Muller","year":"2024","unstructured":"Muller A, Escribano-Subias P, Fernandes CC, et al. Real-world management of patients with pulmonary arterial hypertension: insights from EXPOSURE. Adv Ther. 2024;41(3):1103\u201319.","journal-title":"Adv Ther"},{"key":"2946_CR11","doi-asserted-by":"publisher","first-page":"e12403","DOI":"10.1002\/pul2.12403","volume":"14","author":"S Gaine","year":"2024","unstructured":"Gaine S, Escribano-Subias P, Muller A, et al. Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE. Pulm Circ. 2024;14:e12403.","journal-title":"Pulm Circ"},{"key":"2946_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.1471","volume":"17","author":"International Society for Pharmacoepidemiology","year":"2008","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2946_CR13","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on methodological standards in pharmacoepidemiology (Revision 11). EMA\/95098\/2010. https:\/\/encepp.europa.eu\/encepp-toolkit\/methodological-guide_en#encepp-guide-on-methodological-standards-in-pharmacoepidemiology. Accessed 15 July 2024."},{"issue":"1","key":"2946_CR14","doi-asserted-by":"publisher","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","volume":"60","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311.","journal-title":"Eur Respir J"},{"issue":"6","key":"2946_CR15","doi-asserted-by":"publisher","first-page":"2102419","DOI":"10.1183\/13993003.02419-2021","volume":"59","author":"A Boucly","year":"2022","unstructured":"Boucly A, Weatherald J, Savale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59(6):2102419.","journal-title":"Eur Respir J"},{"issue":"1","key":"2946_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","volume":"18","author":"JG Coghlan","year":"2018","unstructured":"Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18(1):37\u201347.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7","key":"2946_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jacc.2017.12.010","volume":"71","author":"VV McLaughlin","year":"2018","unstructured":"McLaughlin VV, Hoeper M, Channick R, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71(7):752\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2946_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","volume":"156","author":"RL Benza","year":"2019","unstructured":"Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies. Chest. 2019;156(2):323\u201337.","journal-title":"Chest"},{"issue":"4","key":"2946_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.chest.2019.10.043","volume":"157","author":"VV McLaughlin","year":"2020","unstructured":"McLaughlin VV, Channick R, de Marco T, et al. Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. Chest. 2020;157(4):955\u201365.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02946-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02946-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02946-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:40:50Z","timestamp":1724755250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02946-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02946-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tobias J Lange has received speaker fees and\/or consultancy fees and\/or financial and non-financial support for participation in scientific events and\/or participated on a Data Safety Monitoring Board or Advisory Board for Acceleron Pharma, AOP orphan pharmaceuticals, Bayer, BMS, B\u00f6hringer Ingelheim, CGI medicare, Ferrer, Gossamer Bio, Johnson & Johnson, MSD, and Pfizer. Pilar Escribano-Subias has received grants\/research support from Ferrer and GlaxoSmithKline, consulting fees from Johnson & Johnson, Acceleron, Ferrer and MSD, payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Johnson & Johnson, MSD, Ferrer and AOT, has received support from Johnson & Johnson and MSD for attending meetings and\/or travel and has participated on a Data Safety Monitoring Board or Advisory Board for Johnson & Johnson, MSD, Ferrer, Gossamer, AOT, Acceleron and GlaxoSmithKline. Audrey Muller is an employee of Johnson & Johnson and has Johnson & Johnson shares. Catarina C Fernandes is an employee of Johnson & Johnson. Martina Fontana is an employee of Johnson & Johnson and has Johnson & Johnson shares. Tatiana Remenova is an employee of Johnson & Johnson. Stefan S\u00f6derberg has received speaker and consultancy fees, and financial support for participation in scientific events from Johnson & Johnson. Sean Gaine has had relations, such as funding, with the following subjects that have commercial interests in the pharmaceutical and medical field: Aerovate Therapeutics, Acceleron, Altavant, Gossamer Bio, Johnson & Johnson, MSD and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and the protocol was approved at each study site (and at the national level in Sweden), by an institutional review board or independent ethics committee and the study was conducted in accordance with the International Society for Pharmacoepidemiology (ISPE) <i>Guidelines for Good Pharmacoepidemiology Practices (GPP)<\/i> and in accordance with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) <i>Guide on Methodological Standards in Pharmacoepidemiology<\/i>. Written informed consent was obtained from each patient for accessing, processing and using anonymised patient data in scientific research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}